B
VYGR icon

Bailard’s Voyager Therapeutics VYGR Stock Holding History

Bailard’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,700
Closed -$128K – 825
2024
Q1 		$128K Buy
+13,700
New +$116K ﹤0.01% 716
2022
Q4 		– Sell
-28,900
Closed -$171K – 788
2022
Q3 		$171K Buy
+28,900
New +$185K 0.01% 616
2020
Q2 		– Sell
-140,700
Closed -$1.29M – 562
2020
Q1 		$1.29M Sell
140,700
-27,000
-16% -$310K 0.09% 154
2019
Q4 		$2.34M Buy
167,700
+50,200
+43% +$730K 0.13% 141
2019
Q3 		$2.02M Buy
117,500
+76,500
+187% +$1.61M 0.12% 154
2019
Q2 		$1.12M Buy
+41,000
New +$938K 0.07% 214
2018
Q4 		– Sell
-22,000
Closed -$416K – 564
2018
Q3 		$416K Hold
22,000
– – 0.02% 418
2018
Q2 		$430K Buy
22,000
+2,000
+10% +$39.5K 0.03% 399
2018
Q1 		$376K Buy
20,000
+6,000
+43% +$130K 0.02% 383
2017
Q4 		$232K Buy
+14,000
New +$240K 0.01% 405

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bailard's VYGR Position: Q2 2024 in Review

Bailard sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 13,700 shares — an estimated $128K sold.

Bailard first reported a position in VYGR in Q4 2017 and held it in 10 quarters. The position peaked at $2.34M in Q4 2019. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

  • Bailard reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bailard sold 13,700 Voyager Therapeutics shares in Q2 2024, an estimated $128K.
  • Bailard first reported a position in Voyager Therapeutics in Q4 2017 and held it in 10 quarters.
  • Bailard's Voyager Therapeutics position peaked at $2.34M in Q4 2019.
  • 127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on Bailard's 13F filing for Q2 2024, filed 25 Jul 2024.